Weath­er­ing the storm: An­oth­er biotech braves Covid-19 in up­sized IPO

Keros Ther­a­peu­tics has man­aged to ex­e­cute an IPO, hit­ting the top end of its pric­ing range and sell­ing more … their CD20XCD30 bispecific now being tested in a range of blood cancers, in …
( read original story …)


Search your Hotel